{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"3.7","value":"3.4"},{"comment":"The upper limit of the CI is below the level of detection.","groupId":"OG001","lowerLimit":"1.58","upperLimit":"NA","value":"1.82"},{"comment":"There is only one participant, so statistics cannot be calculated.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort C (Ewing/Ewing-like sarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG000","title":"Cohort C: Ewing Sarcoma"},{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG001","title":"Cohort D: Rhabdomyosarcoma"},{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG002","title":"Cohort E: Mesenchymal Chondrosarcoma"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 16 weeks","title":"Progression-free Survival (PFS). Cohort C, Cohort D, and Cohort E","type":"PRIMARY","unitOfMeasure":"months"}